Vericel CORP 8-K filings

Vericel Corporation announced robust second quarter 2026 financial results, exceeding expectations with a 22% revenue increase and raising full-year guidance, alongside a new $200 million share repurchase program.

Vericel Corporation has updated its bylaws to reflect its relocation to a new global headquarters in Burlington, Massachusetts.

Vericel Corporation announced robust first quarter 2026 financial results, with total revenue up 30% to $68.4 million, and raised its full-year revenue guidance.

Vericel Corporation reported robust financial results for the fourth quarter and full-year 2025, driven by significant revenue and profit growth across its advanced therapies.

Vericel Corporation announced preliminary, unaudited financial results for fiscal year 2025, projecting strong revenue growth and profitability, driven by record MACI performance.

Vericel Corporation announced record third quarter 2025 financial results, driven by strong MACI revenue growth and significant profitability improvements.

Vericel Corporation announced robust second-quarter 2025 financial results, featuring 20% total revenue growth, 112% adjusted EBITDA growth, and significant margin expansion, while reaffirming full-year profitability guidance.

Vericel Corporation announced record first quarter MACI revenue of $46.3 million and total revenue of $52.6 million, while also raising full-year profitability guidance.

Vericel Corporation's shareholders approved the Amended and Restated 2022 Omnibus Incentive Plan and the Amended and Restated 2015 Employee Stock Purchase Plan at the Annual Meeting held on April 30, 2025.

Vericel Corporation expects minimal impact from recently announced U.S. tariffs and potential retaliatory actions due to its domestic operations and significant safety stock.

Vericel Corporation announces a 20% increase in full-year total revenue to $237.2 million, fueled by growth in both MACI and Burn Care segments, alongside significant improvements in profitability.

Vericel Corporation reports preliminary 2024 financial results with 20% revenue growth and forecasts continued growth and profitability improvements for 2025 and beyond.

Vericel Corporation announced a strong third quarter with a 27% increase in total revenue, driven by growth in both MACI and Burn Care products, and raised its full-year profitability guidance.

Vericel Corporation has received FDA approval for its MACI Arthro product, enabling less invasive arthroscopic delivery of its cartilage repair therapy.

Vericel Corporation announced FDA approval for NexoBrid to treat severe thermal burns in pediatric patients, expanding its market to include approximately 20 pediatric burn centers.

Vericel Corporation announced record second-quarter revenue, driven by strong growth in MACI and NexoBrid, and raised its full-year profitability guidance.

Vericel Corporation announced a 25% increase in total revenue to $51.3 million for the first quarter of 2024, driven by strong growth in both MACI and burn care products, and raised its full-year revenue guidance.

Vericel Corporation held its annual shareholder meeting on May 1, 2024, where shareholders voted on the election of directors, executive compensation, and the ratification of the company's accounting firm.

Vericel Corporation announced a 20% increase in full-year revenue to $197.5 million and a 40% growth in adjusted EBITDA, alongside positive guidance for 2024.